Indoor Mold and Damp Buildings

Breathing · §16

Live in a damp building and you cough more, wheeze more, catch more colds, and — if you have asthma — reach for the inhaler more often. That isn't folk wisdom. The WHO, the US Institute of Medicine, the EPA, and three independent meta-analyses all converge on it. Roughly 1 in 8 cases of childhood asthma in damp housing traces back to the housing itself. The intervention is unglamorous: keep indoor humidity under 50%, dry water spills within two days, fix what's leaking. The complications are the marketing layer on top — the air spore tests, the urinary "mycotoxin" panels, the multi-thousand-dollar "mold detox" protocols — most of which the evidence does not support.

Avoid · As-needed Evidence Strong Chapter Breathing

A musty smell, a stain on the ceiling, a basement that always feels heavy — these are the cheap signals to act on. Fix the moisture, remove what's grown, keep a hygrometer reading under 50% in living spaces, and most of the cough, the congestion, the recurring sinus pressure starts walking back on a scale of weeks. The harder part isn't the science; it's not getting sold expensive tests for a disease the tests can't actually diagnose.

What "damp building" means to your body: a slurry of spores, fungal fragments, irritant chemicals from waterlogged drywall and carpet, and the dust mites and bacteria that bloom in the same wet places. You breathe the mix. Some of it triggers allergy — fungal proteins are potent allergens. Some of it triggers irritation in airways even without allergy. Some of it, in people with asthma, sets off the cascade that ends in a worse week.

This is settled at the level public-health bodies issue guidelines on. The Institute of Medicine reviewed the literature in 2004 and called the evidence "sufficient" for the association between damp / mouldy indoor environments and upper-respiratory symptoms, cough, wheeze, and asthma symptoms in sensitized people IOM 2004. The WHO issued formal indoor-air-quality guidelines on dampness and mould in 2009 — the first WHO IAQ guidelines on a biological exposure — and concluded that occupants of damp buildings have up to 75% greater risk of respiratory symptoms and asthma WHO 2009.

The quantitative meta-analysis (Fisk et al. 2007) pooled the underlying studies and produced odds ratios of 1.34 to 1.75 across the main outcomes — upper-respiratory symptoms, cough, wheeze, ever-asthma, current asthma, and asthma development — with 9 of 10 confidence intervals excluding the null. A later meta-analysis specifically on incident asthma (Quansah et al. 2012) found water damage, visible mould, and mould odour each independently raised the risk of developing new asthma. The 2015 update to the IOM asthma-exacerbation review formally upgraded dampness-related exposure to a causal relationship with asthma exacerbation in children Kanchongkittiphon et al. 2015. Rhinitis has its own meta-analysis (Jaakkola et al. 2013) showing dampness and mould raise both ever- and current-rhinitis odds by roughly 40–50%.

What none of these reviews find is the dramatic "toxic mold" story that dominates the consumer internet — the systemic, multi-organ, mycotoxin-poisoning narrative. The doses of airborne mycotoxin measured in even heavily contaminated buildings sit orders of magnitude below the doses that produce systemic toxicity in animal models Chang and Gershwin 2019. The disease the evidence actually supports is more pedestrian: irritated airways, allergic noses, sensitized lungs. Pedestrian and real.

What the consumer story gets wrong

"Black mold is uniquely deadly." The species you're being told to fear is Stachybotrys chartarum, which got its reputation from a 1990s cluster of infant lung haemorrhages in Cleveland. When the CDC re-examined the cases, the causal link to Stachybotrys didn't hold up IOM 2004. Stachybotrys is one of dozens of damp-building organisms; the actionable exposure is "visible mould plus a moisture problem," not "which species is on the wall." Treating it like it does fits the marketing of testing services; the evidence does not back the distinction Chang and Gershwin 2019.

"Test the air. Test your urine for mycotoxins." Airborne spore counts vary day to day, lack reference ranges, and don't tell a contractor anything they couldn't see by walking the building. Urinary mycotoxin panels — typically $200–$800 from a commercial lab — pick up background mycotoxin exposure from food (coffee, grains, nuts contain measurable mycotoxins as a baseline) and are not validated as diagnostics for inhalational illness Chang and Gershwin 2019 ACMT 2025. The CDC, EPA, and WHO all explicitly recommend against routine testing as a basis for action — find the moisture and the mould visually, then fix them.

"Bleach it." The EPA explicitly does not recommend bleach as routine mould cleanup. Dead mould is still allergenic. Sterilising a surface doesn't fix the moisture that grew the colony, so it grows back. Bleach vapour adds an airway irritant exposure, and bleach mixed with ammonia-based cleaners produces chlorine gas — a real ER visit EPA 2012. The actual goal is removal: clean the surface with detergent and water, dry it, and stop the leak.

"My fatigue / brain fog / autonomic symptoms must be the mould." This is the contested frontier. A clinician-led movement built around "Chronic Inflammatory Response Syndrome" (CIRS) attributes multi-system illness to water-damaged buildings and sells a multi-month "mould detox" protocol. Mainstream toxicology, allergy, and pulmonary medicine — UCLA Health, the American College of Medical Toxicology, the journals that publish the systematic reviews above — do not recognise CIRS as a discrete diagnosis: the biomarkers cited move with too many other things, the symptom cluster is nearly identical to chronic-fatigue syndrome and other functional syndromes, and the protocols haven't been validated in controlled trials Chang and Gershwin 2019 ACMT 2025. None of this means the suffering is fake; it means the diagnostic label may not be what's actually going on, and the protocols sold against the label run into thousands of dollars without controlled-trial evidence behind them.

Who needs to take this seriously, not casually

For most healthy adults, a damp patch in a bathroom corner is a fix-it project, not an emergency. For four groups it's neither.

People on chemotherapy, transplant immunosuppressants, or with neutropenia / advanced HIV. Environmental fungal exposure can cause invasive aspergillosis — rare in the general population, lethal often enough that hematology and transplant teams give explicit mould-avoidance instructions during high-risk windows IOM 2004 WHO 2009.
Children, especially toddlers and primary-school-age. The causal link with asthma exacerbation is strongest in children, and the WHO attributes about 13% of childhood asthma in developed-world damp housing to the housing WHO 2009 Kanchongkittiphon et al. 2015.
Anyone with asthma, COPD, cystic fibrosis, or known mould allergy. Damp housing measurably worsens control. The flip side: remediation produces some of the largest symptom reductions documented in the intervention literature Sauni et al. 2015.
Anyone doing DIY cleanup with bleach. Don't mix bleach with ammonia-based cleaners. Ventilate. Wear a respirator (N95 minimum) and gloves for anything bigger than a small bathroom patch EPA 2012.

What to actually do

The protocol from the EPA, the CDC, and the WHO is the same protocol, and it's not complicated: control moisture, dry fast when something gets wet, remove visible growth, fix the source.

Buy a hygrometer. Twenty dollars at any hardware store. Keep one in any room that runs damp — basement, bathroom, bedroom on an exterior wall. Target indoor relative humidity between 30% and 50%; never let it sit above 50% for long CDC 2022.
Run a dehumidifier with an adjustable humidistat in any space the hygrometer says is over 50%. Set the target to 45% and let it cycle itself. Basements and crawlspaces need a unit rated for the lower temperatures down there.
The 48-hour rule. If anything gets wet — pipe leak, spill, washing-machine overflow, rain through a window — dry it within 24 to 48 hours. After that, mould starts establishing on porous materials (drywall, carpet, ceiling tile) and they typically need to come out rather than be cleaned EPA 2012.
Cleanup scale matters. Visible growth under about 10 ft² (a square roughly three feet on a side) is DIY territory: detergent and water, scrub, dry, ventilate. Growth between 10 and 100 ft², or any contamination in HVAC ducts, is professional remediation. Anything bigger or post-flood: hire a remediation contractor with verifiable references EPA 2008.
Find the source. Cleaning the visible growth without fixing what's leaking is the most common failure mode — colonies regrow within weeks. Check roof flashing, gutters, window seals, plumbing under sinks, bathroom ventilation, basement waterproofing, and HVAC condensate lines.
Ventilate bathrooms and kitchens. Use the exhaust fan during and after showering / cooking; confirm it vents outside, not into an attic.

What's not on the list: routine air-spore testing, urinary mycotoxin panels, "mould-illness" supplement stacks, ozone generators (which produce a lung irritant of their own). HEPA air purifiers reduce airborne spore counts but don't address growth or moisture; useful as a complement during remediation, not a substitute for fixing the building.

What it costs in money and time

Damp housing is common — 5–30% prevalence in cold climates, up to 60% in warm and humid ones, depending on building stock and ventilation Quansah et al. 2012. So is dealing with it.

The buy-once toolkit is cheap. A hygrometer runs about $15–$25. A dehumidifier with an adjustable humidistat that covers most homes is $200–$400; basement-rated and large-area units climb toward $600. That's the prevention stack for the majority of cases.

Reactive cleanup scales with the problem. Small DIY jobs are detergent, gloves, and an N95 — call it under $50. Professional remediation of a medium contamination (10–100 ft², or HVAC involvement, or anything behind drywall) typically runs $500–$3,000. A whole-house event — finished-basement flood, long-undetected leak — can run $10,000–$30,000 or higher, especially if porous materials need replacement. Homeowner's insurance covers some water-damage events (a burst pipe) but typically excludes others (gradual leaks, groundwater flooding without a flood rider) — read the policy before you need it.

The time cost is mostly front-loaded. Once moisture sources are addressed and humidity is under control, the recurring effort is a five-minute monthly walk through the spots where damp tends to start: under sinks, behind toilets, window frames, the basement, anywhere on an exterior wall in a closet that doesn't get airflow. The dehumidifier runs itself.

What ignoring it actually looks like

For an adult who shrugs at the bathroom corner or the basement smell: not much, at first. Then a winter where you notice you've had three colds in a row and one turned into bronchitis. A spring where the morning congestion that you assumed was seasonal allergies just doesn't lift. If you have asthma you already know — the rescue inhaler comes out more often, sleep gets choppier, the stairs feel harder. The forecast isn't dramatic; the dampness is just quietly subtracting from how you breathe and how you sleep. The Cochrane review's flip side gives the magnitude: remediated homes see asthma-related outcomes fall by roughly 40% in adults Sauni et al. 2015. That's what you're leaving on the table.

For a child in a damp home it's heavier. The 30–50% bump in odds of developing asthma is real, and once asthma is established it's a lifelong condition Quansah et al. 2012. The school nurse calls more often. The PE teacher notices. The number of childhood-asthma cases in damp Western housing that trace back to the housing itself is about one in eight WHO 2009. That's not the kid who was going to develop asthma anyway — that's the kid who got it because of where they grew up.

For an immunocompromised host on chemotherapy, transplant immunosuppression, or with neutropenia, the stakes are different in kind: invasive aspergillosis is rare, but it's the kind of rare that ends in the ICU IOM 2004.

What changes once you fix it

The first week after the leak is patched and the wet drywall is out: less of the musty smell you'd stopped noticing because it had been there for months. Within a few weeks, the morning congestion that you'd quietly accepted as "how I wake up" gets shorter. If you've been on a daily antihistamine for what you thought was allergies, you may start forgetting to take it and not notice. Cough at night drops out. The colds-and-bronchitis cycle thins.

On the timescale the intervention studies measure — weeks to a few months — adults in remediated homes use less asthma medication and report fewer respiratory symptoms Sauni et al. 2015. Children in remediated homes have fewer asthma symptom days. The effect isn't subtle. It's the reason public-health bodies recommend remediation as the action even though they can't randomise people into living in dry vs damp houses.

Two honest limits. Sensitization, once established, doesn't reverse. If you've spent years becoming allergic to Aspergillus or Alternaria, you stay allergic — but the reactivity drops when the antigen load drops. And if your symptoms include fatigue, cognitive complaints, or autonomic problems that you've attributed to "mould illness," the remediation literature isn't strong evidence those will resolve, because the evidence base for the broader syndrome doesn't exist Chang and Gershwin 2019. The respiratory and allergic story is the part with the receipts.

Adjacent things worth knowing about

Indoor air quality more broadly — particulate matter, gas stoves, ventilation, CO₂ levels. Same buildings, different exposures.
Asthma — if you have it, mould is one of several environmental triggers worth managing alongside dust mites, pet dander, smoke, and cold air.
Allergic rhinitis — the diagnosis and management story for chronic nasal symptoms, of which mould allergy is one cause.
Chronic rhinosinusitis — when nasal symptoms persist past three months, mould allergy is one of several contributors worth ruling in or out.
Radon — different gas, similar story: another invisible indoor exposure that public-health bodies recommend testing for, and that the housing industry doesn't reliably surface.

Related in the handbook

Worsens / aggravates

— Mold can't grow without moisture — keeping indoor humidity under 50% is the root fix.
— Damp housing drives asthma — roughly one in eight childhood cases traces back to the building itself.
— Mold spores are a year-round allergen — a damp home keeps the nose congested and the sinuses flaring.

Helps

— A HEPA filter catches spores in the air — but it's a band-aid until you fix the moisture feeding the mold.
— While you fix the damp, a saline rinse can ease the sinus congestion and pressure that mold spores stir up.

— Mold is a major contributor to poor indoor air; controlling it is part of the same project.
— A damp bedroom shows up in the bed first: clammy sheets and mite-friendly bedding. Fix the moisture at the source.

Substance and claimed effects

Indoor mold exposure is shorthand for occupancy of a building with persistent dampness sufficient to sustain microbial growth on interior surfaces or within building materials. The substance is not a single fungus but a community: filamentous fungi (Cladosporium, Penicillium, Aspergillus, Alternaria, Stachybotrys chartarum), the bacteria and house-dust mites that co-thrive in damp matrices, and the volatile and particulate emissions damp materials release. Exposure is overwhelmingly inhalational. Claims this entry covers as consequences: increased upper and lower respiratory symptoms (cough, wheeze, shortness of breath), increased respiratory tract infections, increased asthma exacerbation in people with established asthma, increased asthma incidence (especially in children), increased allergic rhinitis, increased rhinosinusitis (including the specific entity allergic fungal rhinosinusitis), hypersensitivity pneumonitis in susceptible hosts, invasive fungal disease in the immunocompromised, and a contested broader chronic-multisystem-illness construct (variously "toxic mold syndrome," CIRS / Chronic Inflammatory Response Syndrome) which mainstream toxicology and allergy organisations reject as a discrete diagnostic entity Chang and Gershwin 2019, ACMT 2025. The action is avoidance via moisture control and remediation; the cadence is as-needed when damp/visible mold is discovered.

Evidence by addressing question

Mechanism

Damp building materials release a complex mixture of biological and chemical agents. Fungal spores, hyphal fragments, and submicron particles are inhalable and reach upper and lower airways. Fungal cell-wall components — (1→3)-β-D-glucans, chitin, mannans — are immunologically active and stimulate innate immune receptors (Dectin-1, TLR2, TLR4) on airway epithelium and alveolar macrophages, driving neutrophilic and Th2-skewed inflammation Mendell et al. 2011. Mold-derived proteases (e.g., Asp f 1 from Aspergillus fumigatus, Alt a 1 from Alternaria alternata) are potent allergens that drive IgE-mediated sensitization and Th2 cytokine release (IL-4, IL-5, IL-13), the substrate for allergic rhinitis and allergic asthma. Microbial volatile organic compounds (MVOCs) and emissions from water-degraded building materials add irritant exposure. Mycotoxins (aflatoxins, ochratoxins, satratoxins, trichothecenes) are well-characterised toxins at high ingested doses in agricultural / occupational settings, but airborne mycotoxin concentrations in damp homes are orders of magnitude below thresholds shown to produce systemic toxicity in any species; the WHO and IOM reviews found no evidence that inhalational mycotoxin doses in residential exposure produce systemic disease WHO 2009, IOM 2004, Chang and Gershwin 2019. The mechanism story that has empirical traction is therefore airway inflammation + allergic sensitization + irritation from a damp-building mixture, not systemic mycotoxicosis.

Evidence

Three overlapping bodies of high-quality synthesis converge. (i) The Institute of Medicine's Damp Indoor Spaces and Health (2004) found sufficient evidence of association between damp / mouldy indoor environments and upper respiratory tract symptoms, cough, wheeze, and asthma symptoms in sensitized persons; and between mold exposure and hypersensitivity pneumonitis in susceptible hosts IOM 2004. (ii) Fisk, Lei-Gomez, and Mendell's quantitative meta-analysis pooled the IOM-reviewed studies plus additional papers and produced central odds-ratio estimates of 1.34 to 1.75 for the association of home dampness/mold with upper respiratory symptoms, cough, wheeze, ever-asthma, current asthma, and asthma development, with 95% CIs excluding the null in 9 of 10 outcomes Fisk et al. 2007. (iii) WHO's Guidelines for Indoor Air Quality: Dampness and Mould (2009) graded the evidence as sufficient to recommend prevention/remediation as public-health policy, estimating that approximately 13% of childhood asthma in the WHO European Region could be attributable to damp housing WHO 2009. Subsequent meta-analyses sharpened sub-claims: Quansah et al. (2012) found dampness, visible mould, and mould odour each significantly elevated incident-asthma risk in prospective cohorts (pooled ORs ~1.3–1.5; mould odour the strongest predictor) Quansah et al. 2012. Jaakkola et al. (2013) found dampness/mould significantly associated with both ever-rhinitis and current rhinitis (pooled ORs ~1.4–1.5) Jaakkola et al. 2013. The Kanchongkittiphon et al. (2015) update to the IOM asthma-exacerbation review explicitly upgraded dampness-related agents to a causal association with asthma exacerbation in children Kanchongkittiphon et al. 2015. The body of evidence is observational (residential exposures cannot be randomised), but the consistency across geographies, climate zones, study designs, and exposure-assessment methods is the basis for the causal upgrade.

Protocol

The intervention literature is small relative to the observational literature, but it points the same way. The Cochrane review (Sauni et al. 2015) of eight controlled trials (three RCTs, five non-RCTs; n=6538) found that remediating dampness and mould reduced asthma-related symptoms and respiratory infections compared with no intervention, with adult asthma-medication-use odds ratios near 0.6 after remediation in pooled analyses Sauni et al. 2015. EPA and CDC public-health guidance converges on the same protocol: control moisture (keep indoor relative humidity below 50%, ideally 30–50%); dry water-damaged materials within 24–48 hours of any leak/spill (the window before mould establishes on porous materials); remove and replace porous materials wet beyond 48 hours rather than attempt cleaning; for visible mold cover less than ~10 ft², homeowner cleanup with detergent and water is appropriate; for larger contamination or any HVAC involvement, professional remediation; biocides (bleach) are not recommended as routine practice — dead mold remains allergenic, and the goal is removal not sterilization EPA 2012, EPA 2008, CDC 2022. Source-control of moisture is the rate-limiting step: removing visible growth without fixing the leak/condensation/poor ventilation reliably regrows the colony within weeks.

Contraindications

"Contraindications" here invert — there are populations for whom continued exposure is uniquely dangerous and remediation uniquely urgent. Immunocompromised hosts (haematologic malignancy, post-transplant, neutropenia, advanced HIV, high-dose corticosteroid therapy) are at risk of invasive aspergillosis and other invasive mycoses from environmental fungal exposure IOM 2004, WHO 2009. People with established asthma, COPD, or known mold allergy have measurably worse outcomes living in damp homes and are the population in whom remediation produces the largest symptom reduction Kanchongkittiphon et al. 2015, Sauni et al. 2015. Cystic fibrosis patients risk colonisation with Aspergillus fumigatus and allergic bronchopulmonary aspergillosis. Children are the population in whom dampness-related agents have a causal exacerbation relationship with asthma and the largest attributable-fraction signal WHO 2009, Kanchongkittiphon et al. 2015. Bleach + ammonia mixtures during DIY cleanup produce chlorine gas — a real and recurring exposure injury EPA 2012.

Misconceptions

The literature flags several widely-held positions that do not survive review.

"Toxic black mold" (Stachybotrys chartarum) is uniquely dangerous. The original 1990s Cleveland infant pulmonary haemorrhage cluster prompted the IOM review; on re-examination, the CDC concluded the original Stachybotrys causal attribution was not supported by the evidence. Stachybotrys is one of many damp-building organisms and the species ID does not determine clinical risk — the relevant exposure variable is dampness/visible mold and odour, not which fungus IOM 2004, Chang and Gershwin 2019.
Air mycotoxin testing / urinary mycotoxin testing diagnoses mold illness. Neither test is validated; both are marketed by commercial labs without supporting clinical evidence Chang and Gershwin 2019, ACMT 2025.
You need air spore counts to know if you have a mold problem. WHO, CDC, IOM, and EPA converge: visible mold and a moisture problem are the actionable exposures. Spore counts vary day to day, lack reference ranges, and do not guide remediation WHO 2009, EPA 2012, Chang and Gershwin 2019.
Bleach the mold. EPA explicitly does not recommend biocides as routine cleanup — dead mold is still allergenic, biocide vapour adds an irritant exposure, and sterilization is neither possible nor the goal EPA 2012.

Audience

Children (especially aged 1–7), people with asthma, people with mold-allergic rhinitis or chronic rhinosinusitis, immunocompromised hosts, and people living in low-income or poorly-maintained housing all carry disproportionate burden. The WHO review explicitly flags housing-quality inequity as an amplifier — damp housing is concentrated in populations already carrying higher disease burden WHO 2009. Otherwise-healthy adults living briefly in damp environments may experience cough, eye irritation, or rhinitis symptoms that resolve on exposure removal without lasting consequences.

Failure-modes

Three failure modes recur in the practitioner literature. (i) Cosmetic-only cleanup — wiping or painting over visible growth without fixing the moisture source — yields recolonisation within weeks EPA 2008. (ii) Underestimating concealed growth: a wall-stain or musty smell often signals contamination behind drywall, under carpet, in HVAC ductwork, or in attic insulation; surface area visible may be <10% of total contamination. (iii) Mis-spent diagnostic effort: patients with non-specific symptoms order air spore counts or urinary mycotoxin panels (commonly $200–$800 out of pocket), get positive results from background environmental spores or non-specific assays, and pursue expensive "mold detox" protocols whose evidence base does not exist Chang and Gershwin 2019, ACMT 2025.

Practicalities

Residential dampness is common: 5–30% prevalence in cold climates, 10–60% in moderate and warm climates depending on stock, ventilation, and climate exposure Quansah et al. 2012. Detection tools that do work: a $20 hygrometer to verify indoor RH stays under 50%; visual inspection of bathrooms, kitchens, basements, around windows, behind furniture on exterior walls, under sinks; following any musty odour to its source. Remediation costs scale with area: DIY for <10 ft²; professional remediation for 10–100 ft² typically runs $500–$3,000; whole-house remediation after a major water event can run $10,000–$30,000+. A dehumidifier with adjustable humidistat (~$200–$400) is the single most reliable preventive purchase for damp climates and basements. HEPA-filter air purifiers reduce airborne spore counts but do not address growth or the underlying moisture; treating the air without treating the source is a failure mode EPA 2012, CDC 2022.

Stakes

For a child growing up in a damp home: roughly 30–50% higher odds of developing asthma over childhood, persistent rhinitis and cough, more respiratory infections per year, and disproportionate school absence on the back of it Quansah et al. 2012, WHO 2009, Kanchongkittiphon et al. 2015. For an adult with asthma in a damp home: more rescue-inhaler use, more night-time symptoms, more exacerbations, worse exercise tolerance Kanchongkittiphon et al. 2015. For an immunocompromised host, occupancy of a damp building is a survivable but real invasive-mycosis risk. For the otherwise-healthy adult, the realistic stakes are months of low-grade rhinitis, recurrent sinus infection, sleep disruption from nasal congestion, and the financial cost of either remediation or moving.

Payoff

The remediation literature shows symptom reduction on timescales of weeks to months. In Sauni et al.'s pooled analysis, adult respiratory and asthma outcomes improved with odds ratios near 0.6 — roughly a 40% reduction — after dampness remediation in homes Sauni et al. 2015. The payoff is symmetric to the stakes: rhinitis and cough resolve, asthma control improves, respiratory infection frequency drops. Latency varies — irritant and rhinitis symptoms often improve within days of exposure removal; allergic sensitization, once established, does not reverse but reactivity drops when antigen exposure drops.

History

Recognition of damp-building illness in the modern public-health literature traces to the 1990s "sick building syndrome" research and the Cleveland infant acute idiopathic pulmonary haemorrhage cluster (1993–1994), which prompted CDC investigation and the eventual IOM 2004 review IOM 2004. WHO followed with its 2009 dampness/mould guidelines — the first WHO indoor-air-quality guidelines on a biological agent WHO 2009. In parallel, a clinician-led movement (Shoemaker and successors) developed the CIRS / "biotoxin illness" construct from the late 1990s, claiming a multi-organ inflammatory syndrome caused by water-damaged-building biotoxin exposure. Mainstream allergy, toxicology, and pulmonary societies have consistently declined to recognise CIRS as a discrete diagnostic entity, citing absent validated diagnostic criteria, biomarker irreproducibility, and symptom overlap with chronic-fatigue / fibromyalgia / functional syndromes Chang and Gershwin 2019, ACMT 2025. This is the credibility-range fault line.

Out-of-scope

Not covered: occupational mould exposure (sawmill workers, farmers, cheese/wine workers — different exposure intensities, regulated under occupational health frameworks); deliberate ingestion of mold-contaminated food (a distinct mycotoxin / aflatoxin problem); outdoor mold spore allergy; specific allergy immunotherapy regimens; the ABPA (allergic bronchopulmonary aspergillosis) workup in CF / asthma. These either warrant their own entries or sit inside other entries (asthma, CF, immunocompromise).

The credibility range

Optimist case (for the broader chronic-illness construct)

Proponents (Shoemaker; integrative and functional-medicine clinicians; the CIRS literature) argue mainstream medicine is anchored on an outdated framework: it acknowledges allergic and asthma effects but misses a distinct biotoxin-mediated chronic inflammatory pathway. They cite immune-marker abnormalities (TGF-β1 elevations, C4a, MMP-9, low VIP / MSH), HLA-DR genetic susceptibility patterns, neurocognitive deficits on standardised testing in exposed cohorts, and clinical response to a defined treatment protocol (binders, antifungals, VIP nasal spray, environmental remediation). They argue that patient-reported recoveries on the Shoemaker protocol, while uncontrolled, are too numerous and reproducible to be placebo. Mechanistically, they point to the documented existence of mycotoxin toxicity at high doses as proof of biological plausibility for lower-dose chronic effects. The pattern — community signal preceding formal science — they argue is a recurring story in environmental medicine (asbestos, lead, tobacco), and dismissing it on RCT-purity grounds risks under-recognising real disease.

Skeptic case

Mainstream toxicology, allergy, and pulmonary medicine reject CIRS as a discrete entity. The skeptic case: airborne mycotoxin concentrations measured in even heavily mold-contaminated buildings are orders of magnitude below doses that produce systemic toxicity in any animal or human model — the dose-response argument that grounds toxicology cannot be discarded selectively Chang and Gershwin 2019, ACMT 2025. The biomarkers cited (C4a, TGF-β1, MMP-9) are non-specific inflammatory markers that move with many conditions and don't discriminate exposed from unexposed in controlled comparisons. Urinary mycotoxin testing detects background dietary mycotoxin exposure (humans ingest measurable levels routinely from grains, coffee, nuts) and does not reflect inhalational dose. The CIRS symptom cluster overlaps almost entirely with ME/CFS, fibromyalgia, depression, and functional somatic syndromes — populations highly responsive to attentional, narrative, and placebo effects. Commercial incentive structures (mold-testing labs, remediation contractors, and CIRS-protocol clinics) create amplification independent of biology. The skeptic case is not that mold doesn't cause disease — it does (asthma, rhinitis, sinusitis, hypersensitivity pneumonitis, invasive disease in immunocompromised) — but that the additional chronic-multisystem-illness layer is not supported by reproducible evidence.

Author's call

The respiratory / allergic effects are settled science — WHO, IOM, CDC, EPA, and three independent meta-analyses converge, with the IOM update recognising a causal association for asthma exacerbation in children WHO 2009, IOM 2004, Kanchongkittiphon et al. 2015. The entry should land confidently on the respiratory/allergic story, recommend moisture control and remediation as the action, and treat the "toxic mold syndrome / CIRS" construct as a contested adjacent claim. The article should name the contested construct honestly (readers encounter it constantly), explain what evidence actually exists vs what's marketed, and flag the financial/diagnostic trap (paid mold panels, urinary mycotoxin tests, expensive "detox" protocols) without dismissing the suffering of people who have landed in that diagnostic frame. Evidence score for the core respiratory claims: 5. Controversy on the headline claim (mold → respiratory/allergic disease): 1. Controversy if the broader chronic-illness construct were the headline claim: 4. The entry's headline claim is the respiratory/allergic one; the contested construct lives inside misconceptions.

Stakeholder and incentive map

Public-health bodies (WHO, CDC, EPA, NICE): converge on dampness control as policy. Conservative framing, focused on housing quality as social determinant.
Allergy / pulmonary medicine: recognise mold as allergic / asthmatic trigger and as cause of specific entities (HP, AFRS, ABPA, invasive aspergillosis); reject systemic-mycotoxicosis framing.
Toxicology societies (ACMT): explicitly reject CIRS / inhalational mycotoxin systemic illness as established ACMT 2025.
Integrative / functional medicine, CIRS clinicians: advocate the broader biotoxin-illness model, paid panels, multi-month protocols. Financial incentive aligned with diagnosis breadth.
Mold-testing labs and remediation contractors: commercial incentive for testing and large-scope remediation. Some legitimate, some exploit fear.
Plaintiff-side toxic-tort bar: economic incentive in litigation framing mold exposure as systemic injury; influenced earlier 2000s public perception.
Patient advocacy communities (water-damaged-building patient groups, online communities): authentic suffering, often after long diagnostic odysseys; high attribution to mold often runs ahead of evidence but reflects real morbidity that does not map cleanly to mainstream diagnosis.
Landlords / housing authorities: counter-incentive to remediate (cost); the equity dimension WHO flags.

Population variability

Children show the largest effect sizes for both asthma incidence and exacerbation; the causal IOM-update designation is for children specifically Kanchongkittiphon et al. 2015.
Atopic individuals (existing allergic disease, eczema, family history) sensitize more readily and experience symptoms at lower exposures.
People with established asthma: clear exacerbation effect; remediation produces measurable control improvement Sauni et al. 2015.
Immunocompromised hosts: rare but severe invasive disease risk; mold avoidance is a real medical recommendation for hematology / transplant patients during high-risk periods.
People with CF: distinct ABPA / Aspergillus colonisation risk profile.
Older adults: less data; mechanisms suggest similar respiratory effects with possibly increased infection susceptibility.
Low-income housing residents: WHO flags the structural concentration of damp housing in populations with the least ability to remediate WHO 2009.
Otherwise-healthy adults without atopy: smallest and least durable effects — typically irritant symptoms while exposed, resolving on removal.

Knowledge gaps

Open questions where evidence would change the call. (i) Dose-response for specific microbial agents — current evidence anchors on visible / odour-detectable dampness, not on measured concentrations of any single fungus or toxin. (ii) Whether HLA-DR susceptibility patterns claimed by CIRS proponents replicate in independent cohorts under blinded protocols. (iii) Mechanistic accounting for the symptom cluster (cognitive complaints, fatigue, autonomic symptoms) reported by patients who attribute illness to water-damaged buildings — whether this is mediated by anxiety / sleep disruption / rhinitis-driven inflammation / a yet-unidentified pathway, or by classification with non-specific functional syndromes. (iv) Whether HEPA filtration, beyond moisture control + remediation, produces additive symptom reduction. (v) Cost-effectiveness of universal dampness remediation in public housing on respiratory-disease incidence and absenteeism. (vi) Whether modern "tight" building envelopes (energy-efficient construction without adequate ventilation) are widening the population at risk; WHO flags this trend but quantitative data is thin WHO 2009.

Scope vs brief. The brief named respiratory infections, asthma, allergic rhinitis, sinus disease, the contested broader chronic-illness construct, and remediation. The article covers all six. The contested construct (CIRS / "toxic mold syndrome") is addressed inside misconceptions rather than as a standalone section — placing it on equal footing with the settled respiratory science would mis-signal parity of evidence. Sinus disease specifically is covered at evidence-level via rhinitis meta-analysis (Jaakkola 2013) and the allergic fungal rhinosinusitis literature, surfaced briefly in mechanism/evidence and as an out-of-scope pointer; a dedicated section would have inflated length without adding new claims.

Hard call: how skeptical to be on CIRS. The author's call lands with mainstream toxicology/allergy (Chang & Gershwin 2019, ACMT 2025), but the writing tries not to dismiss the lived experience of patients in that diagnostic frame — the calibrated position is "the suffering is real, the label and the protocols are not validated." This was the most contested editorial choice; the alternative (giving CIRS more space as a legitimate-but-emerging construct) would have misrepresented current consensus.

Rating difficulties. longevity at 1 is conservative; the WHO childhood-asthma attributable fraction argues for higher, but the population-level mortality signal is small and the score reflects the typical adult reader. sleep and energy at 1 each are secondary effects via rhinitis/congestion — defensible but not load-bearing. controversy at 2 reflects that the entry's headline claim is uncontroversial; if the entry's centre were the CIRS construct it would be 4.

Future-link candidates that don't yet exist. Asthma (entry), allergic rhinitis, chronic rhinosinusitis, radon, indoor air quality / ventilation, gas-stove combustion products. The out-of-scope section names these explicitly so a future editor can wire related links once they land.

Separate-entry candidates surfaced during writing. Allergic fungal rhinosinusitis (specialist topic, narrow audience). Hypersensitivity pneumonitis (overlaps with occupational exposure). Invasive aspergillosis in immunocompromised hosts (clinical, not lifestyle). "CIRS / biotoxin illness" as a dedicated controversy entry — defensible if the catalogue grows a "contested-diagnosis" beat.

Excluded from the article. Occupational mould exposure (different regulatory frame, different doses); aflatoxin food contamination (ingested, not inhaled); outdoor mould spore allergy seasonality; specific allergy-immunotherapy regimens for fungal sensitization. The dossier flags all of these in §3i.